Outcomes of patients on maintenance dialysis hospitalized with covid-19

Mount Sinai COVID Informatics Center (MSCIC)

doi:10.2215/CJN.12360720

Outcomes of patients on maintenance dialysis hospitalized with covid-19

Mount Sinai COVID Informatics Center (MSCIC)

Research output: Contribution to journal › Letter › peer-review

10 Scopus citations

Original language	English
Pages (from-to)	452-455
Number of pages	4
Journal	Clinical Journal of the American Society of Nephrology
Volume	16
Issue number	3
DOIs	https://doi.org/10.2215/CJN.12360720
State	Published - 2021

Access to Document

10.2215/CJN.12360720

Cite this

@article{02cee763653c4147822924eb8bb4bf4c,

title = "Outcomes of patients on maintenance dialysis hospitalized with covid-19",

author = "{Mount Sinai COVID Informatics Center (MSCIC)} and Lili Chan and Jaladanki, {Suraj K.} and Sulaiman Somani and Ishan Paranjpe and Arvind Kumar and Shan Zhao and Lewis Kaufman and Staci Leisman and Shuchita Sharma and He, {John Cijiang} and Barbara Murphy and Fayad, {Zahi A.} and Levin, {Matthew A.} and Bottinger, {Erwin P.} and Charney, {Alexander W.} and Glicksberg, {Benjamin S.} and Coca, {Steven G.} and Nadkarni, {Girish N.}",

note = "Funding Information: E.P. Bottinger reports consultancy agreements with Deloitte and Roland Berger; ownership interest in Digital Medicine E.B{\"o}ttinger GmbH, EBCW GmbH, and Ontomics, Inc.; receiving honoraria from Bayer, Bosch Health Campus, Sanofi, and Siemens; and serving as a scientific advisor or member of Bosch Health Campus and Seer Biosciences Inc. L. Chan reports receiving research funding from the National Institutes of Health (R01AG066471) and consulting fees from GLG consulting, outside the submitted work. S.G. Coca reports employment with Icahn School of Medicine at Mount Sinai (Mount Sinai owns part of Renalytix AI); consultancy agreements with Akebia, Bayer, Boehringer Ingelheim, CHF Solutions, Goldfinch Bio, inRegen, Quark, Relypsa, Renalytix AI, and Takeda; ownership interest in pulseData and Renalytix AI; receiving Funding Information: This study received support from National Institute of Diabetes and Digestive and Kidney Diseases grant K23DK107908. Funding Information: research funding from inRegen and Renalytix AI; patents and inventions with Renalytix AI; serving as a scientific advisor or member of Renalytix AI; and serving as an associate editor for Kidney360 and on the editorial board for JASN, CJASN,and Kidney International. S.G. Coca is supported by the following grants: U01DK106962, R01DK115562, R01HL085757, U01OH011326, R01DK112258, and RRTI UG 2019. Z.A. Fayad reports consultancy agreements and ownership interest in Trained Therapeutix Discovery; receiving research funding from the National Institutes of Health; patents and inventions with Trained Therapeutix Discovery; and serving as a scientific advisor or member of Trained Therapeutix Discovery. J. He reports consultancy agreements and ownership interest in Renalytix AI; receiving research funding from Shangpharma Innovation; receiving honoraria from Otsuka; and serving as a scientific advisor or member of the editorial board for Kidney International and JASN, a board member of the Chinese American Society of Nephrology and the International Chinese Society of Nephrology, an associate editor for Kidney Disease, and a section editor for Nephron. B. Murphy reports consultancy agreements with Regeneron and Renalytix AI; ownership interest in Renalytix AI; receiving research funding from the National Institutes of Health; patents and inventions with Fractal Dx; serving on the advisory board for ITBmed, as a board member of Renalytix AI, on the scientific advisory board for Veloxis, and on the advisory board for Vertex; and other interests/relationships with DSMBHansa–DSMB. She is a nonexecutive director of Renalytix AI. G.N. Nadkarni reports employment with, consultancy agreements with, and ownership interest in Pensieve Health and Renalytix AI; receiving consulting fees from AstraZeneca, BioVie, GLG Consulting, and Reata; and serving as a scientific advisor or member of Pensieve Health and Renalytix AI. G.N. Nadkarni is supported by a career development award from the National Institute of Diabetes and Digestive and Kidney Diseases (K23DK107908) and is also supported by R01DK108803, U01HG007278,U01HG009610,andU01DK116100.S.Somanireports consultancy agreements and ownership interest in Monogram Orthopedics. All remaining authors have nothing to disclose.",

year = "2021",

doi = "10.2215/CJN.12360720",

language = "English",

volume = "16",

pages = "452--455",

journal = "Clinical journal of the American Society of Nephrology : CJASN",

issn = "1555-9041",

publisher = "American Society of Nephrology",

number = "3",

}

TY - JOUR

T1 - Outcomes of patients on maintenance dialysis hospitalized with covid-19

AU - Mount Sinai COVID Informatics Center (MSCIC)

AU - Chan, Lili

AU - Jaladanki, Suraj K.

AU - Somani, Sulaiman

AU - Paranjpe, Ishan

AU - Kumar, Arvind

AU - Zhao, Shan

AU - Kaufman, Lewis

AU - Leisman, Staci

AU - Sharma, Shuchita

AU - He, John Cijiang

AU - Murphy, Barbara

AU - Fayad, Zahi A.

AU - Levin, Matthew A.

AU - Bottinger, Erwin P.

AU - Charney, Alexander W.

AU - Glicksberg, Benjamin S.

AU - Coca, Steven G.

AU - Nadkarni, Girish N.

N1 - Funding Information: E.P. Bottinger reports consultancy agreements with Deloitte and Roland Berger; ownership interest in Digital Medicine E.Böttinger GmbH, EBCW GmbH, and Ontomics, Inc.; receiving honoraria from Bayer, Bosch Health Campus, Sanofi, and Siemens; and serving as a scientific advisor or member of Bosch Health Campus and Seer Biosciences Inc. L. Chan reports receiving research funding from the National Institutes of Health (R01AG066471) and consulting fees from GLG consulting, outside the submitted work. S.G. Coca reports employment with Icahn School of Medicine at Mount Sinai (Mount Sinai owns part of Renalytix AI); consultancy agreements with Akebia, Bayer, Boehringer Ingelheim, CHF Solutions, Goldfinch Bio, inRegen, Quark, Relypsa, Renalytix AI, and Takeda; ownership interest in pulseData and Renalytix AI; receiving Funding Information: This study received support from National Institute of Diabetes and Digestive and Kidney Diseases grant K23DK107908. Funding Information: research funding from inRegen and Renalytix AI; patents and inventions with Renalytix AI; serving as a scientific advisor or member of Renalytix AI; and serving as an associate editor for Kidney360 and on the editorial board for JASN, CJASN,and Kidney International. S.G. Coca is supported by the following grants: U01DK106962, R01DK115562, R01HL085757, U01OH011326, R01DK112258, and RRTI UG 2019. Z.A. Fayad reports consultancy agreements and ownership interest in Trained Therapeutix Discovery; receiving research funding from the National Institutes of Health; patents and inventions with Trained Therapeutix Discovery; and serving as a scientific advisor or member of Trained Therapeutix Discovery. J. He reports consultancy agreements and ownership interest in Renalytix AI; receiving research funding from Shangpharma Innovation; receiving honoraria from Otsuka; and serving as a scientific advisor or member of the editorial board for Kidney International and JASN, a board member of the Chinese American Society of Nephrology and the International Chinese Society of Nephrology, an associate editor for Kidney Disease, and a section editor for Nephron. B. Murphy reports consultancy agreements with Regeneron and Renalytix AI; ownership interest in Renalytix AI; receiving research funding from the National Institutes of Health; patents and inventions with Fractal Dx; serving on the advisory board for ITBmed, as a board member of Renalytix AI, on the scientific advisory board for Veloxis, and on the advisory board for Vertex; and other interests/relationships with DSMBHansa–DSMB. She is a nonexecutive director of Renalytix AI. G.N. Nadkarni reports employment with, consultancy agreements with, and ownership interest in Pensieve Health and Renalytix AI; receiving consulting fees from AstraZeneca, BioVie, GLG Consulting, and Reata; and serving as a scientific advisor or member of Pensieve Health and Renalytix AI. G.N. Nadkarni is supported by a career development award from the National Institute of Diabetes and Digestive and Kidney Diseases (K23DK107908) and is also supported by R01DK108803, U01HG007278,U01HG009610,andU01DK116100.S.Somanireports consultancy agreements and ownership interest in Monogram Orthopedics. All remaining authors have nothing to disclose.

PY - 2021

Y1 - 2021

UR - http://www.scopus.com/inward/record.url?scp=85102724770&partnerID=8YFLogxK

U2 - 10.2215/CJN.12360720

DO - 10.2215/CJN.12360720

M3 - Letter

C2 - 33127607

AN - SCOPUS:85102724770

SN - 1555-9041

VL - 16

SP - 452

EP - 455

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

IS - 3

ER -